London School of Hygiene and Tropical Medicine homepage
All experts
All experts

Katie Patterson

Research Fellow

Infection Biology

Orcid identifier0000-0002-4500-7199
  • Research Fellow
    Infection Biology

RESEARCH INTERESTS

I specialise in multiplex immunoassays and sero-epidemiology for malaria. My PhD uses multiplex antibody detection assays to investigate the acquisition of natural immunity in children receiving RTS,S/AS01E with or without SMC in Burkina Faso and Mali, and in children receiving different R21 vaccine regimens in Burkina Faso.

 

My broader work spans multi-disease sero-surveillance, assay development and technical transfer to international partners. This includes SARS-CoV-2 assay development and transfer to laboratories in Africa; harmonisation of malaria, SARS-CoV-2 and NTD panels for integrated sero-surveillance studies; and multiplex serology applied to Ebola vaccine trials and immune-modulating coinfections. I also use multiplex cytokine, chemokine, subclass and avidity assays to characterise immune activation and disease signatures across diverse settings in Africa and Asia.

GRANTS

  • Showing page 1 out of 1
Showing page 1, grants 1 to 3 of 3
  • EXTERNALLY HELD RESEARCH GRANT
    The Partnership for Research on Ebola VACcinations-extended follow-UP and clinical research capacity building build-UP
    European and Developing Countries Clinical Trials Partnership1 Oct 2021
    People funded by this grant: Patterson C
  • EXTERNALLY HELD RESEARCH GRANT
    Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (RTSS-SMC)
    PATH5 Jun 2020
    People funded by this grant: Patterson C
    A double-blind, individual randomised trial will be undertaken in children under five years of age living in areas of Burkina Faso or Mali where the transmission of malaria is intense and highly seasonal to determine whether administration of further doses of the malaria vaccine RTS,S/AS01 at the beginning of the malaria transmission until children reach the age of five years is (a) as effective as SMC with SP + AQ in preventing clinical malaria (b) provides additional, useful protection when given together with SMC. The primary trial end-point will be the incidence of clinical episodes of malaria detected by passive case detection. This is a two year extension of the current RTS,S/AS01 + SMC trial to continue the trial until the study children reach the age of five years, the current age at which SMC is recommended until.
  • EXTERNALLY HELD RESEARCH GRANT
    Countrywide Mortality Surveillance for Action (COMSA)
    Bill and Melinda Gates Foundation1 Apr 2020
    People funded by this grant: Patterson C, Tetteh K, Drakeley C
    Aims to improve the lives of Mozambicans by producing continuous annual data on mortality and cause of death and national and provincial levels for use by the government and policy-makers. COMSA is led and implemented by the Government of Mozambique through the National Institute of Statistics and the National Institute of Health with technical assistance and advice from Johns Hopkins University.